Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New 3D-Guided radiation boost aims to hit prostate tumors more precisely

NCT ID NCT05322356

Disease control Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small study tests whether a 3D ultrasound system can help doctors place extra radioactive iodine seeds precisely into prostate tumors. Fifteen men with low- or intermediate-risk prostate cancer will receive the boost during standard brachytherapy. The main goal is to see if the seeds land in the right spot, not yet to measure cancer control or side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
iodine-125 radioactive implant
What this could lead to
If successful, this could improve precision in delivering radiation boosts to prostate tumors, potentially reducing side effects.
What could go wrong
This is a very small, early feasibility study with only 15 participants. It is not designed to prove effectiveness or safety, and the approach may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years * Patient to be treated with brachytherapy * Patient with low or favorable intermediate risk prostate adenocarcinoma ISUP 1 and 2, G6 (3+3) or G7 (3+4) * Life expectancy of more than 10 years * PSA (prostate-specific antigen) \< 15 ng/ml * cT1c or cT2a or cT2b * Prostate volume ≤ 60 cc * ECOG Performance status 0-2 * Patient is affiliated to a health insurance system * Patient who has signed consent form Exclusion Criteria: * Patient with urinary function disorders IPSS\> 14 * Prostate volume \> 60cc. * Gleason 7(4+3) or Gleason score ≥8 * PSA ≥ 15 ng/ml * Patient with metastases * Hormone therapy with antiandrogen or LHRH analogue * History of abdominopelvic irradiation * Inflammatory digestive disease (haemorrhagic rectocolitis, Crohn's disease) * Interventional study in progress that may interfere with the present study * Protected persons (patient concerned by articles L1121-5, L1121-6, L1121-8 of the French public health code)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Low or favorable intermediate risk prostate adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Isabelle Boudry

    Grenoble, 38043, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.